We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

161 hedge funds and large institutions have $1.43B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 52 increasing their positions, 52 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

466% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $3.23M

125% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 12

10% more funds holding

Funds holding: 147 → 161 (+14)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 52

8% less capital invested

Capital invested by funds: $1.56B → $1.43B (-$129M)

Holders
161
Holders Change
+14
Holders Change %
+9.52%
% of All Funds
2.82%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
27
Increased
52
Reduced
52
Closed
12
Calls
$18.3M
Puts
$3.23M
Net Calls
+$15.1M
Net Calls Change
+$10.9M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$23.9M
2
EAM
Eventide Asset Management
Massachusetts
+$12.8M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$8.28M
4
SCM
Suvretta Capital Management
New York
+$6.69M
5
AC
Armistice Capital
New York
+$6.57M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$35.6M
2
DM
Deerfield Management
New York
-$16.9M
3
CCM
Consonance Capital Management
New York
-$14.2M
4
TCM
Tekla Capital Management
Massachusetts
-$11.3M
5
Alkeon Capital Management
Alkeon Capital Management
New York
-$8.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
51
Adage Capital Partners
Massachusetts
$3.4M +$3.19M +100,000 New
SA
52
Sunesis Advisors
Kansas
$3.27M – – –
Hudson Bay Capital Management
53
Hudson Bay Capital Management
Connecticut
$3.23M -$4.87M -152,500 -62%
SSA
54
Schonfeld Strategic Advisors
New York
$3.22M +$1.8M +56,369 +147%
Swiss National Bank
55
Swiss National Bank
Switzerland
$3.04M +$22.3K +700 +0.8%
Russell Investments Group
56
Russell Investments Group
United Kingdom
$3M -$606K -18,997 -18%
Citigroup
57
Citigroup
New York
$2.77M -$1.12M -35,015 -30%
PPA
58
Parametric Portfolio Associates
Washington
$2.67M +$939K +29,427 +60%
Susquehanna International Group
59
Susquehanna International Group
Pennsylvania
$2.41M -$72.9K -2,284 -3%
HWAM
60
Hennion & Walsh Asset Management
New Jersey
$2.36M +$222K +6,964 +11%
Wells Fargo
61
Wells Fargo
California
$2.35M -$4.69M -147,092 -68%
Rafferty Asset Management
62
Rafferty Asset Management
New York
$2.24M -$247K -7,731 -10%
Barclays
63
Barclays
United Kingdom
$2.16M +$1.06M +33,186 +109%
GCP
64
GSA Capital Partners
United Kingdom
$2.06M +$1.93M +60,550 New
RPAM
65
Rhenman & Partners Asset Management
Sweden
$2.04M – – –
Citadel Advisors
66
Citadel Advisors
Florida
$1.99M -$3.36M -105,334 -64%
AllianceBernstein
67
AllianceBernstein
Tennessee
$1.88M – – –
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$1.85M +$4.56K +143 +0.3%
State of Wisconsin Investment Board
69
State of Wisconsin Investment Board
Wisconsin
$1.76M – – –
LP
70
LMR Partners
United Kingdom
$1.74M +$1.64M +51,335 New
Point72 Asset Management
71
Point72 Asset Management
Connecticut
$1.73M -$3.68M -115,174 -69%
PVI
72
Pura Vida Investments
New York
$1.7M +$1.6M +50,000 New
Morgan Stanley
73
Morgan Stanley
New York
$1.59M +$89.3K +2,799 +6%
RhumbLine Advisers
74
RhumbLine Advisers
Massachusetts
$1.5M +$39.2K +1,227 +3%
SCM
75
Silverarc Capital Management
Massachusetts
$1.27M -$255 -8 -0%
1 2
3
4 5

DCPH Hedge Fund Activity: Q3 2021 in Review

161 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2021, worth a combined $1.43B — down 8.3% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new DCPH positions and 12 closed out — a net gain of 15 holders — while 52 added to existing stakes and 52 trimmed.

The largest buyer was Logos Global Management, adding an estimated $23.9M. The largest seller was OrbiMed, cutting an estimated $35.6M.

  • 161 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2021, up from 147 in Q2 2021.
  • Funds reported $1.43B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 8.3% quarter-over-quarter.
  • 27 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 12 closed out, a net change of +15 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Logos Global Management, an estimated $23.9M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was OrbiMed, an estimated $35.6M sold.

Based on aggregated 13F filings for Q3 2021.